Blurring the line between in vitro and in vivo testing.
Efficiently advancing or eliminating drug or nutritional targets early in the development process simultaneously reduces R&D cost and increases R&D capacity.
Organoid technology dramatically improves translation compared to standard in vitro assays, allowing for early selection and focus on the most promising drug and nutrition candidates. As a result, organoids reduce or even eliminate live animal studies and their associated costs, while accelerating the development process.
3D Health Solution's partnership with the U.S. FDA Center for Veterinary Medicine meets objectives that are outlined in the Modernization Act 2.0, which has ambitions to eliminate the requirement for live animal testing.
Our technology is being developed in partnership with the U.S. FDA Center for Veterinary Medicine, the National Science foundation and the National Cancer Institute.
3D Health Solutions provides research services to several of the world's leading nutrition and pharmaceutical companies, and also academic institutions, including those below who's identities we are allowed to share.
We would be happy to answer any questions you have or schedule a web conference to present our data.
If you would like to join our mailing list please enter your email below. We won't overwhelm you.